Champions Oncology, Inc.

CSBR
$4.97 (+ $0.00 + 0.00%)
Last updated: 2026-08-25 14:38 UTC
CSBR Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS15870P3073
CUSIP15870P307
Market Price4.97
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio41.65
EPS0.17
Market Cap$98.3M
Book Value0.3
Price to Book23.6
Beta0.95
52w High11.99
52w Low5.59
Next Earnings DateN/A

Champions Oncology, Inc. trades under ticker CSBR on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US15870P3073, CUSIP 15870P307. Also searched as Champions Oncology.

Related researchCSBR stock priceCSBR share price15870P307Champions Oncology stockChampions Oncology share price
About the Company
Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.
Price History